Abgenix, Inc. (ABGX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (312)	2/4/2004 5:32:29 PM
From: Icebrg	Read Replies (1) of 590

>>It would really be interesting to hear what Abgenix think that they are doing.>> Withy talked a little about this at the Merril Lynch presentation. The main potential advantages might be: - The drug "will" have a direct dose-dependent impact on the PTH-levels. The mAb binds directly to PTH, while alternative drugs (like for example NPSP/Amgen's Cinacalcet) works indirectly. - Abgenix expects their drug to have a long(er) half-life making it possible to tailor administration of the drug to the dialyses these patients are receiving. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next